Evidence map›Paper›PMID 32182548›Full record

ArticleOral oncology2020

Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.

Dan Fan, Jung J Kang, Ming Fan, Huili Wang, Anna Lee, Yao Yu, Linda Chen, C Jillian Tsai, Sean M McBride, Nadeem Riaz and 13 more

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. A scoping review of patient selection methods for proton therapy.Journal of medical radiation sciences · 2022
    Article
  11. Article
  12. Immunomodulatory Effects of Radiotherapy.International journal of molecular sciences · 2020
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 2 countries.

Dan FanDepartment of Radiation Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jung J KangDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ming FanDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Huili WangDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China.
Anna LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yao YuDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Linda ChenDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
C Jillian TsaiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sean M McBrideDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nadeem RiazDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daphna Y GelblumDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brian P NealProCure Proton Therapy Center, Somerset, NJ, USA.
James FettenDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lara A DunnDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Loren S MichelDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jay O BoyleDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc A CohenDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin R RomanDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ian GanlyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Bhuvanesh SinghDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard J WongDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric J ShermanProCure Proton Therapy Center, Somerset, NJ, USA.
Nancy Y LeeDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: leen2@mskcc.org.
Memorial Sloan Kettering Cancer Center · USProCure (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectivesPatients with prior irradiated head and neck cancer (HNC) who are ineligible for definitive retreatment have limited local palliative options. We report the largest series of the use of the Quad Shot (QS) regimen as a last-line local palliative therapy. MATERIALS AND

methodsWe identified 166 patients with prior HN radiation therapy (RT) treated with QS regimen (3.7 Gy twice daily over 2 consecutive days at 4 weeks intervals per cycle, up to 4 cycles). Palliative response defined by symptom(s) relief or radiographic tumor reduction, locoregional progression free survival (LPFS), overall survival (OS) and radiation-related toxicity were assessed.

resultsMedian age was 66 years. Median follow-up for all patients was 6.0 months and 9.7 months for living patients. Overall palliative response rate was 66% and symptoms improved in 60% of all patients. Predictors of palliative response were > 2 year interval from prior RT and 3-4 QS cycles. Median LPFS was 5.1 months with 1-year LPFS 17.7%, and median OS was 6.4 months with 1-year OS 25.3%. On multivariate analysis, proton RT, KPS > 70, presence of palliative response and 3-4 QS cycles were associated with improved LPFS and improved OS. The overall Grade 3 toxicity rate was 10.8% (n = 18). No Grade 4-5 toxicities were observed.

conclusionPalliative QS is an effective last-line local therapy with minimal toxicity in patients with previously irradiated HNC. The administration of 3-4 QS cycles predicts palliative response, improved PFS, and improved OS. KPS > 70 and proton therapy are associated with survival improvements.

Indexed as

AgedFemaleHead and Neck NeoplasmsHumansMaleProton TherapySurvival AnalysisHead and neck cancerPalliative radiationProton radiation therapyQuad ShotReirradiation

Identifiers

PMID32182548
PMCPMC8480112
OpenAlexW3011669569

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.